NCT06176261
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs treatment 2 recruiting NCT04150042
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells treatment 1 recruiting NCT05327608
Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery No drug interventions supportive_care Not Available suspended NCT06016738
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer No drug interventions treatment 3 recruiting NCT02157051
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer No drug interventions treatment 1 active_not_recruiting NCT04379570
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy No drug interventions health_services_research 3 recruiting NCT01881230
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) treatment 2 / 3 completed NCT05512364
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) No drug interventions treatment 3 recruiting NCT05524584
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer No drug interventions treatment 2 recruiting NCT05101564
Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer No drug interventions treatment 2 active_not_recruiting NCT04764084
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors No drug interventions treatment 1 unknown_status NCT04762979
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer No drug interventions treatment 2 recruiting NCT03412643
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling No drug interventions treatment 2 recruiting NCT04576143
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer No drug interventions treatment 2 / 3 recruiting NCT01372579
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients No drug interventions treatment 2 unknown_status NCT01042379
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer No drug interventions treatment 2 recruiting NCT01037790
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer No drug interventions treatment 2 completed NCT06525675
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) Not Available Not Available active_not_recruiting NCT06488378
Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer No drug interventions treatment 1 recruiting NCT06382948
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. treatment 3 not_yet_recruiting NCT06375798
Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer No drug interventions Not Available Not Available recruiting NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC treatment 1 / 2 suspended NCT06102824
Organoid-based Functional Precision Therapy for Advanced Breast Cancer treatment 2 recruiting NCT05989347
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy other 1 not_yet_recruiting NCT05508906
Phase 1b Combo w/ Ribociclib and Alpelisib treatment 1 recruiting NCT05305924
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer treatment 2 recruiting NCT05275777
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer treatment 1 / 2 active_not_recruiting NCT05163106
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole treatment 2 completed NCT04848454
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy treatment 2 recruiting NCT04742959
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors treatment 1 / 2 completed NCT04660435
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer No drug interventions Not Available Not Available recruiting NCT04588298
A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer treatment 2 completed NCT04499118
AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer treatment 2 unknown_status NCT04504916
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) treatment 2 terminated NCT04230109
Sacituzumab Govitecan In TNBC treatment 2 recruiting NCT04624711
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer treatment 2 unknown_status NCT05025735
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer treatment 2 unknown_status NCT05029999
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer treatment 1 recruiting NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy treatment 2 recruiting NCT05452213
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients treatment 4 recruiting NCT05333328
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk No drug interventions treatment 4 recruiting NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors treatment 1 recruiting NCT02273752
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer treatment 2 terminated NCT02015559
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus No drug interventions supportive_care 2 completed NCT01368263
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer treatment 2 terminated NCT01208441
RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer treatment 1 terminated NCT01104259
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer treatment 1 completed NCT06568692
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer No drug interventions treatment 2 recruiting NCT06518837
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer No drug interventions treatment 2 not_yet_recruiting NCT06407401
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer No drug interventions supportive_care 3 not_yet_recruiting NCT06348654
New Digital Person-based Care Model in Patients With HER2-negative Advanced Breast Cancer No drug interventions Not Available Not Available not_yet_recruiting NCT06040593
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer No drug interventions Not Available Not Available completed NCT05982093
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer No drug interventions treatment 2 recruiting NCT05826964
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer No drug interventions treatment 2 recruiting NCT05759949
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors No drug interventions treatment 1 active_not_recruiting NCT05660083
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) No drug interventions treatment 2 recruiting NCT05503108
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer No drug interventions treatment 3 suspended NCT05504707
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer No drug interventions treatment 1 recruiting NCT05467891
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer treatment 2 recruiting NCT05263882
Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer treatment 2 unknown_status NCT05173103
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer No drug interventions Not Available Not Available recruiting NCT05150652
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer No drug interventions treatment 2 recruiting NCT05054374
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer treatment 1 / 2 completed NCT04965688
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition No drug interventions treatment 2 recruiting NCT04942054
A Study in Patients With Advanced Breast Cancer No drug interventions treatment 1 terminated NCT04901299
Fulvestrant + Neratinib In Breast Cancer No drug interventions treatment 2 withdrawn NCT04738292
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) No drug interventions treatment 2 terminated NCT04985266
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer treatment 2 recruiting NCT04573231
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer diagnostic 2 recruiting NCT04498793
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer No drug interventions treatment 2 unknown_status NCT04504331
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer treatment 1 terminated NCT04450706
Functional Precision Oncology for Metastatic Breast Cancer No drug interventions treatment Not Available recruiting NCT06334432
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT03989089
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation No drug interventions treatment 2 unknown_status NCT03983954
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors No drug interventions treatment 1 active_not_recruiting NCT04551495
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) No drug interventions treatment 2 active_not_recruiting NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer No drug interventions treatment 1 recruiting NCT05334147
Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer No drug interventions Not Available Not Available not_yet_recruiting NCT05253053
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT05607004
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer No drug interventions treatment 2 recruiting NCT05594095
SNF Platform Study of HR+/ HER2-advanced Breast Cancer No drug interventions treatment 2 recruiting NCT05870813
CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer No drug interventions Not Available Not Available recruiting NCT05868226
PRE-I-SPY Phase I/Ib Oncology Platform Program treatment 1 recruiting NCT05889390
Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer No drug interventions treatment 2 / 3 recruiting NCT03294694
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer treatment 1 terminated NCT03251378
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer No drug interventions treatment 1 active_not_recruiting NCT02269670
Phase II Study of Everolimus Beyond Progression No drug interventions treatment 2 terminated NCT02371174
Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan. No drug interventions Not Available Not Available completed NCT02225470
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes No drug interventions treatment 3 completed NCT01953588
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery No drug interventions treatment 3 active_not_recruiting NCT01938833
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer No drug interventions treatment 1 / 2 terminated NCT01791478
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer No drug interventions treatment 1 active_not_recruiting NCT01705691
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer treatment 2 completed NCT01234532
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery No drug interventions treatment 2 terminated NCT01217411
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer No drug interventions treatment 1 terminated NCT01158274
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors treatment 1 completed NCT01151449
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer No drug interventions treatment 2 terminated NCT00679029
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer No drug interventions treatment 2 terminated NCT00031681
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) treatment 1 completed NCT00003440
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic treatment 3 completed NCT01527487
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer No drug interventions treatment 2 completed NCT01840306
Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer No drug interventions Not Available Not Available completed NCT06570031
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer No drug interventions treatment 1 active_not_recruiting NCT06516289
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab No drug interventions treatment 2 not_yet_recruiting NCT06388122
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients No drug interventions Not Available Not Available recruiting NCT06253195
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT06230055
Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis No drug interventions treatment 4 recruiting NCT05396612
Role of the Immune Environment in Response to Therapy in Breast Cancer No drug interventions Not Available Not Available recruiting NCT05383196
Onvansertib + Paclitaxel In TNBC No drug interventions treatment 1 / 2 recruiting NCT04595565
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer No drug interventions treatment 3 active_not_recruiting NCT04505826
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer No drug interventions treatment 1 / 2 active_not_recruiting NCT04448886
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC No drug interventions treatment 2 active_not_recruiting NCT03746431
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection No drug interventions treatment 1 / 2 recruiting NCT03613181
ANG1005 in Leptomeningeal Disease From Breast Cancer No drug interventions treatment 3 not_yet_recruiting NCT03575065
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China No drug interventions treatment 2 completed NCT05340413
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. No drug interventions diagnostic 2 recruiting NCT05252416
(VELA) Study of BLU-222 in Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT05683418
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors No drug interventions treatment 1 recruiting NCT05904730
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations No drug interventions treatment 1 enrolling_by_invitation NCT04584255
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer No drug interventions treatment 2 recruiting NCT02315196
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer No drug interventions treatment 2 active_not_recruiting NCT01818063
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer No drug interventions treatment 2 completed NCT01100489
Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer No drug interventions treatment 2 withdrawn NCT00733408
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer No drug interventions treatment 2 completed NCT00618657
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting No drug interventions treatment 2 completed NCT00194792
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer treatment 2 terminated NCT04276272
D4 Choline Breast PET/CT No drug interventions Not Available Not Available completed NCT03568448
Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging No drug interventions Not Available Not Available recruiting NCT03462251
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line No drug interventions treatment 3 completed NCT05398861
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer treatment 2 not_yet_recruiting NCT05761470
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation treatment 2 recruiting NCT03799692
Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer No drug interventions treatment 4 unknown_status NCT05677802
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer No drug interventions health_services_research Not Available recruiting NCT05488145
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy No drug interventions health_services_research Not Available recruiting NCT06534125
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer No drug interventions supportive_care Not Available not_yet_recruiting NCT06026657
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer treatment 1 / 2 recruiting NCT06450873
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery treatment 2 not_yet_recruiting NCT06042569
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial No drug interventions treatment 2 recruiting NCT06058377
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer No drug interventions treatment 3 recruiting NCT06112613
Mobile Health for Adherence in Breast Cancer Patients No drug interventions health_services_research Not Available recruiting NCT06008158
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer No drug interventions supportive_care 2 recruiting NCT05464810
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer No drug interventions treatment 0 recruiting NCT04052555
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer treatment 1 active_not_recruiting NCT01548677
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer treatment 2 completed NCT01288261
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer treatment 1 completed NCT01394211
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer treatment 2 terminated NCT01934478
Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer No drug interventions Not Available Not Available completed NCT02824575
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer treatment 1 terminated NCT02806817
ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism basic_science 0 completed NCT06348134
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery treatment 2 not_yet_recruiting NCT06463626
Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study No drug interventions Not Available Not Available completed NCT02871791
Palbociclib With Everolimus + Exemestane In BC treatment 1 / 2 completed NCT05735080
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer No drug interventions treatment 1 / 2 recruiting NCT01905592
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients No drug interventions treatment 3 terminated NCT06338644
Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. No drug interventions Not Available Not Available not_yet_recruiting NCT02623972
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer No drug interventions treatment 2 active_not_recruiting NCT02175446
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients No drug interventions treatment 2 unknown_status NCT03854903
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor No drug interventions treatment 1 active_not_recruiting NCT06264921
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT02404051
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer No drug interventions treatment 3 unknown_status NCT02894398
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant No drug interventions treatment 2 completed NCT03809988
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) No drug interventions treatment 2 completed NCT01918306
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer No drug interventions treatment 1 / 2 terminated NCT01885013
Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients No drug interventions treatment 2 completed NCT03854617
A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer No drug interventions treatment 2 not_yet_recruiting NCT02668666
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer No drug interventions treatment 2 completed NCT01779531
Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients No drug interventions Not Available Not Available unknown_status NCT02823262
A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older No drug interventions health_services_research Not Available terminated NCT01935492
8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer No drug interventions treatment 3 completed NCT06470672
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer No drug interventions treatment 2 not_yet_recruiting NCT03285568
Patterns of Prescribing and Monitoring of Palbociclib No drug interventions Not Available Not Available completed